SPPAM
SRPT icon

Summit Partners Public Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Summit Partners Public Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,000
Closed -$3.64M – 188
2023
Q3 		$3.64M Sell
30,000
-20,000
-40% -$2.26M 0.16% 104
2023
Q2 		$5.73M Buy
+50,000
New +$6.45M 0.21% 97

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Summit Partners Public Asset Management's SRPT Position: Q1 2025 in Review

Summit Partners Public Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 379,150 shares — an estimated $46.1M sold.

Summit Partners Public Asset Management first reported a position in SRPT in Q4 2017 and held it in 12 quarters. The position peaked at $46.1M in Q4 2024. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Summit Partners Public Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 379,150 Sarepta Therapeutics shares in Q1 2025, an estimated $46.1M.
  • Summit Partners Public Asset Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 12 quarters.
  • Summit Partners Public Asset Management's Sarepta Therapeutics position peaked at $46.1M in Q4 2024.
  • 431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2025, filed 15 May 2025.